// App-Quantinova.ai

BSH2020‐OR‐021 : Pomalidomide, bortezomib and dexamethasone after one prior line of therapy in bortezomib‐pretreated multiple myeloma: a subanalysis of the OPTIMISMM phase 3 trial

Researchers

Presenter

  • J. Lindsay

Principal Investigators

  • K. Weisel

  • P. Moreau

  • L. D. Anderson Jr

  • D. White

  • J. San Miguel

  • P. Sonneveld

  • M. Engelhardt

  • M. Jenner

  • A. Corso

  • J. Drig

  • M. Pavic

  • M. Salomo

  • E. Casal

  • R. Jiang

  • S. Srinivasan

  • T. Biyukov

  • L. Grote

  • T. Peluso

  • P. Richardson

Medical Centers

  • East Kent Hospitals University NHS Foundation Trust, Kent & Canterbury Hospital, Canterbury, United Kingdom

  • National and Kapodistrian University of Athens, Athens, Greece

  • Department of Oncology, Haematology and Bone Marrow Transplantation with section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • University Hospital Hotel-Dieu, Nantes, France

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

  • Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain

  • Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

  • Universitatsklinikum Freiburg, Freiburg, Germany

  • Southampton General Hospital, Southampton,

  • Policlinico San Matteo Universita Di Pavia,Pavia,Italy

  • University Hospital of Essen, Essen, Germany

  • Centre Hospitalier Universitaire De Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont,Sherbrooke,Canada

  • Copenhagen Univ Hosp Rigshospitalet, Kobenhavn O, Denmark

  • Bristol-Myers Squibb, Summit, NJ

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA,

Locations

  • United Kingdom

  • Greece

  • Germany

  • France

  • United States

  • Canada

  • Spain

  • Netherlands

  • Italy

  • Denmark

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

  • Peripheral Nervous System

Disease

  • Multiple Myeloma

  • Peripheral neuropathy

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01734928

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved